Drug Profile
BCD 115
Alternative Names: BCD115; JSC BIOCADLatest Information Update: 31 Oct 2021
Price :
$50
*
At a glance
- Originator Biocad
- Class Antineoplastics
- Mechanism of Action Cyclin dependent kinase 19 inhibitors; Cyclin-dependent kinase 8 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Breast cancer
Most Recent Events
- 16 Mar 2021 Discontinued - Phase-II for Breast cancer in Russia (PO)
- 13 Apr 2018 Phase-II clinical trials in Breast cancer in Russia (PO) (Biocad pipeline, April 2018)
- 01 Mar 2018 Biocad completes a phase-I clinical trial in Breast cancer (Late-stage disease, Metastatic disease, Combination therapy) in Russia (PO) (NCT03065010)